{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:05:10Z","timestamp":1792029910710,"version":"4.4.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Liver disease poses a significant global health burden, with steatotic liver disease related to metabolic dysfunction and\/or alcohol use being the most prevalent type. Current risk stratification strategies emphasize detecting advanced fibrosis as a surrogate marker for liver-related events (LREs), such as hospitalization, liver cancer, or death. However, fibrosis alone does not adequately predict imminent outcomes, particularly in fast-progressing individuals without advanced fibrosis at evaluation. This underscores the need for models designed specifically to predict LREs, enabling timely interventions. The Chronic Liver Disease (CLivD) risk score, the dynamic aspartate aminotransferase-to-alanine aminotransferase ratio (dAAR), and the Cirrhosis Outcome Risk Estimator (CORE) were explicitly developed to predict LRE risk rather than detect fibrosis. Derived from general population cohorts, these models incorporate either standard liver enzymes (dAAR and CORE) or risk factors (CLivD), enabling broad application in primary care and population-based settings. They directly estimate the risk of future LREs, improving on traditional fibrosis-focused approaches. Conversely, widely used models like the Fibrosis-4 index and newer ones, such as the LiverRisk and LiverPRO scores, were initially developed to detect significant\/advanced fibrosis or liver stiffness. While not designed for LRE prediction, they have later been analyzed for this purpose. Integrating fibrosis screening with LRE-focused models like CLivD, dAAR, and CORE can help healthcare systems adopt proactive, preventive care. This approach emphasizes identifying individuals at imminent risk of severe outcomes, potentially ensuring better resource allocation and personalized interventions.<\/jats:p>","DOI":"10.1093\/gastro\/goaf028","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T17:22:11Z","timestamp":1741972931000},"source":"Crossref","is-referenced-by-count":3,"title":["Prediction of major liver-related events in the population using prognostic models"],"prefix":"10.1093","volume":"13","author":[{"given":"Fredrik","family":"\u00c5berg","sequence":"first","affiliation":[{"name":"Transplantation and Liver Surgery Unit, Helsinki University Hospital and University of Helsinki , Helsinki,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"M\u00e4nnist\u00f6","sequence":"additional","affiliation":[{"name":"School of Medicine, Institute of Clinical Medicine, University of Eastern Finland , Kuopio,","place":["Finland"]},{"name":"Department of Medicine, Kuopio University Hospital , Kuopio,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2025081215073663500_goaf028-B1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B2","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.jhep.2023.09.018","article-title":"High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology","volume":"80","author":"\u00c5berg","year":"2024","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-01022-y","article-title":"The steatotic liver disease burden paradox: unravelling the key role of alcohol","author":"Torp","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B4","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"key":"2025081215073663500_goaf028-B5","doi-asserted-by":"crossref","first-page":"e0512","DOI":"10.1097\/HC9.0000000000000512","article-title":"Population screening for cirrhosis","volume":"8","author":"Thiele","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025081215073663500_goaf028-B6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2022.02.021","article-title":"Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score","volume":"77","author":"\u00c5berg","year":"2022","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/hep4.1700","article-title":"A dynamic aspartate-to-alanine aminotransferase ratio provides valid predictions of incident severe liver disease","volume":"5","author":"\u00c5berg","year":"2021","journal-title":"Hepatol Commun"},{"key":"2025081215073663500_goaf028-B10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2025081215073663500_goaf028-B12","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0246","article-title":"Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease","author":"Wang","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"2025081215073663500_goaf028-B13","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"key":"2025081215073663500_goaf028-B15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care","volume":"77","author":"Sripongpun","year":"2023","journal-title":"Hepatology"},{"key":"2025081215073663500_goaf028-B17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction","volume":"167","author":"van Kleef","year":"2024","journal-title":"Gastroenterology"},{"key":"2025081215073663500_goaf028-B18","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/S0168-8278(24)00498-7","article-title":"OS-057-YI CORE: a new risk score measuring GGT, AST, and ALT outperforms FIB-4 when predicting the risk of cirrhosis in a primary care setting","volume":"80","author":"Strandberg","year":"2024","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"2025081215073663500_goaf028-B20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.gastro.2019.09.008","article-title":"Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease","volume":"158","author":"Hagstr\u00f6m","year":"2020","journal-title":"Gastroenterology"},{"key":"2025081215073663500_goaf028-B21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B22","doi-asserted-by":"crossref","first-page":"100780","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025081215073663500_goaf028-B23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hep4.1841","article-title":"Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD","volume":"6","author":"Vieira Barbosa","year":"2022","journal-title":"Hepatol Commun"},{"key":"2025081215073663500_goaf028-B24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"2025081215073663500_goaf028-B25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/HEP.0000000000000707","article-title":"Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population","volume":"80","author":"\u00c5berg","year":"2024","journal-title":"Hepatology"},{"key":"2025081215073663500_goaf028-B27","doi-asserted-by":"crossref","first-page":"100925","DOI":"10.1016\/j.jhepr.2023.100925","article-title":"FIB-4 and APRI for cirrhosis detection in a privately insured national cohort","volume":"6","author":"Parikh","year":"2024","journal-title":"JHEP Rep"},{"key":"2025081215073663500_goaf028-B28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.medj.2024.03.003","article-title":"LiverRisk score: an accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population","volume":"5","author":"Liu","year":"2024","journal-title":"Med"},{"key":"2025081215073663500_goaf028-B29","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.jhepr.2024.101169","article-title":"Diagnostic and prognostic performance of the LiverRisk score in tertiary care","volume":"6","author":"Semmler","year":"2024","journal-title":"JHEP Rep"},{"key":"2025081215073663500_goaf028-B30","doi-asserted-by":"crossref","first-page":"e044952","DOI":"10.1136\/bmjopen-2020-044952","article-title":"Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data","volume":"11","author":"Hydes","year":"2021","journal-title":"BMJ Open"},{"key":"2025081215073663500_goaf028-B31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.15718","article-title":"Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease","volume":"44","author":"Li","year":"2024","journal-title":"Liver Int"},{"key":"2025081215073663500_goaf028-B32","doi-asserted-by":"crossref","first-page":"101516","DOI":"10.1016\/j.aohep.2024.101516","article-title":"The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB-4 score in screening the population for liver disease","volume":"29","author":"Li","year":"2024","journal-title":"Ann Hepatol"},{"key":"2025081215073663500_goaf028-B33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/hep4.1844","article-title":"Validation of dynamic aspartate-to-alanine aminotransferase ratio for predicting liver disease mortality","volume":"6","author":"Song","year":"2022","journal-title":"Hepatol Commun"},{"key":"2025081215073663500_goaf028-B34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jhep.2022.04.008","article-title":"A good step toward low-cost prognostication of liver-related outcome awaits more validation","volume":"77","author":"Song","year":"2022","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B35","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.jhep.2023.12.022","article-title":"Predicting risk of chronic liver disease in Chinese adults: external validation of the CLivD score","volume":"80","author":"Pang","year":"2024","journal-title":"J Hepatol"},{"key":"2025081215073663500_goaf028-B36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/00365521.2022.2113130","article-title":"Changes over time in the Chronic Liver Disease risk score predict liver-related outcomes: longitudinal analysis of the Whitehall II study","volume":"58","author":"\u00c5berg","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"2025081215073663500_goaf028-B37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12916-024-03754-9","article-title":"Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults","volume":"22","author":"Cong","year":"2024","journal-title":"BMC Med"},{"key":"2025081215073663500_goaf028-B38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"2025081215073663500_goaf028-B39","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000679","article-title":"Evidence-based criteria for identifying at-risk individuals requiring liver disease screening","author":"\u00c5berg","year":"2025","journal-title":"Hepatol Commun"},{"key":"2025081215073663500_goaf028-B40","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"2025081215073663500_goaf028-B41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/liv.15554","article-title":"Abdominal obesity and alcohol use modify the impact of genetic risk for incident advanced liver disease in the general population","volume":"43","author":"Luukkonen","year":"2023","journal-title":"Liver Int"},{"key":"2025081215073663500_goaf028-B42","doi-asserted-by":"crossref","first-page":"100172","DOI":"10.1016\/j.lanepe.2021.100172","article-title":"Socioeconomic inequalities in the incidence of alcohol-related liver disease: a nationwide Danish study","volume":"8","author":"Askgaard","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2025081215073663500_goaf028-B43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41575-024-01003-1","article-title":"Health disparities in cirrhosis care and liver transplantation","volume":"22","author":"Goldberg","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B44","doi-asserted-by":"crossref","first-page":"e2230426","DOI":"10.1001\/jamanetworkopen.2022.30426","article-title":"Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease","volume":"5","author":"Chhatwal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025081215073663500_goaf028-B45","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1192\/bjo.2023.49","article-title":"Quantifying the psychological and behavioural consequences of a diagnostic label for non-cancer conditions: systematic review","volume":"9","author":"Sims","year":"2023","journal-title":"BJPsych Open"},{"key":"2025081215073663500_goaf028-B46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1468-0009.2009.00563.x","article-title":"The converged experience of risk and disease","volume":"87","author":"Aronowitz","year":"2009","journal-title":"Milbank Q"},{"key":"2025081215073663500_goaf028-B47","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.pec.2021.09.015","article-title":"Acknowledging and addressing the many ethical aspects of disease","volume":"105","author":"Hofmann","year":"2022","journal-title":"Patient Educ Couns"},{"key":"2025081215073663500_goaf028-B48","doi-asserted-by":"crossref","first-page":"101750","DOI":"10.1016\/j.clinre.2021.101750","article-title":"Liver health literacy and social stigma of liver disease: a general population e-survey","volume":"45","author":"Wahlin","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025081215073663500_goaf028-B49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ypmed.2008.12.010","article-title":"Screening for risk of cardiovascular disease is not associated with mental distress: the Inter99 study","volume":"48","author":"J\u00f8rgensen","year":"2009","journal-title":"Prev Med"},{"key":"2025081215073663500_goaf028-B50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/dmrr.917","article-title":"Psychological effects of prevention: do participants of a type 2 diabetes prevention program experience increased mental distress?","volume":"25","author":"Giel","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"2025081215073663500_goaf028-B51","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025081215073663500_goaf028-B52","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ueg2.12323","article-title":"Comparison of various strategies to define the optimal target population for liver fibrosis screening: a population-based cohort study","volume":"10","author":"\u00c5berg","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"2025081215073663500_goaf028-B53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.10.040","article-title":"Disease progression modeling for economic evaluation in nonalcoholic fatty liver disease-a systematic review","volume":"21","author":"Gruneau","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025081215073663500_goaf028-B54","doi-asserted-by":"crossref","first-page":"e00191","DOI":"10.1097\/HC9.0000000000000191","article-title":"Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease","volume":"7","author":"Gruneau","year":"2023","journal-title":"Hepatol Commun"},{"key":"2025081215073663500_goaf028-B55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11606-022-07707-x","article-title":"Revisiting the time needed to provide adult primary care","volume":"38","author":"Porter","year":"2023","journal-title":"J Gen Intern Med"},{"key":"2025081215073663500_goaf028-B56","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/liv.15255","article-title":"Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: a long-term follow-up study","volume":"42","author":"Balkhed","year":"2022","journal-title":"Liver Int"},{"key":"2025081215073663500_goaf028-B57","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001045","article-title":"Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease","author":"Shang","year":"2024","journal-title":"Hepatology"},{"key":"2025081215073663500_goaf028-B58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2468-1253(24)00316-9","article-title":"The promise of automated liver disease risk stratification in primary care","volume":"10","author":"\u00c5berg","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goaf028\/62416377\/goaf028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goaf028\/62416377\/goaf028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T19:07:49Z","timestamp":1755025669000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goaf028\/8078786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goaf028","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"goaf028"}}